KPV or BPC-157: two peptides, two research avenues
KPV and BPC-157 are often mentioned together, and both are found in the KLOW mix. However, they do not share the same origin, size, or research leads. Here are their differences, point by point.
See KPV 10 mg – €59.90See BPC-157 10 mg – €44.90
At a glance
| Criteria | KPV | BPC-157 |
|---|---|---|
| Size | 3 amino acids | 15 amino acids |
| Origin | End of alpha-MSH, a hormone | Sequence derived from a gastric juice protein |
| Main research area | Inflammation, especially of the intestines | Repair of tendons, ligaments and digestive mucosa |
| Human data | None according to the FDA | Three small studies of low quality |
| Anti-doping | Class S0 (not named) | Class S0 (cited as an example by WADA) |
| Our analysis | 98.8%, 11.07 mg per 10 mg | 99.9%, 12.91 mg per 10 mg |
| MyPeptide price | €59.90 for 10 mg | €44.90 for 10 mg |
Origin and structure
KPV is the smaller of the two: three amino acids, lysine, proline, and valine, which form the end of alpha-MSH. It retains the anti-inflammatory effect of this hormone, without its effect on pigmentation.
BPC-157 is a peptide of fifteen amino acids. Its sequence is derived from a protein found in gastric juice. It has no structural relationship with alpha-MSH.
Research areas
Both peptides have been studied primarily in animals, but not for the same reasons:
- For KPV: inflammation, especially in mouse models of colitis, where it enters cells via the PepT1 transporter. Studies also exist on the skin, the eye, and germs.
- For BPC-157: tissue repair, with models of tendon and ligament injury, muscle healing and protection of the digestive mucosa.
The two lines of research converge on the intestine: KPV for inflammation, BPC-157 for mucosal protection.
Human data
For KPV, the FDA indicates that it has identified no human exposure data. For BPC-157, a systematic review published in 2026 included only three studies, involving a total of thirty people. Their quality was judged low, and the level of certainty of the results very low (Poolton et al., 2026). In both cases, no effect was demonstrated in humans.
The status
Neither is authorized as a drug in either Europe or the United States. In July 2026, an FDA advisory committee recommended allowing them in preparations by US pharmacies, and a provisional policy of the US Department of Health has tolerated these preparations since late October 2026. For sports, the World Anti-Doping Agency cites BPC-157 as an example of its S0 class, that of unapproved substances; KPV is not named there, but it falls within its definition.
The mixtures that contain them
- The Wolverine Stack: BPC-157 and TB-500 in the same vial, without KPV. It sells for €49.90.
- KLOW: a mixture of GHK-Cu, BPC-157, TB-500, and KPV. The KLOW guide describes its composition and analysis.
In a mixture, the peptides are lyophilized together and cannot be separated. Single vials allow each peptide to be studied individually.
- KPV: The Complete Guide
- Benefits: what studies say
- Oral or injectable KPV: the forms studied
- Side effects and status
- Our Janoshik (COA) analysis
- KLOW, a mixture that contains KPV
Frequently asked questions
What is the difference between KPV and BPC-157?
KPV has three amino acids and is derived from alpha-MSH; it is being studied for inflammation. BPC-157 has fifteen amino acids and is derived from a gastric juice protein; it is being studied for tissue repair.
Which one is most studied in humans?
None of them have robust trials. BPC-157 has three small, low-quality studies; for KPV, the FDA has identified no human exposure data.
Are there any mixtures that contain both?
Yes, the KLOW, which combines GHK-Cu, BPC-157, TB-500 and KPV. The Wolverine Stack contains BPC-157 and TB-500, but no KPV.
Are KPV and BPC-157 banned by WADA?
They both fall under class S0 of unapproved substances. WADA cites BPC-157 as an example; KPV is not named.
Are KPV and BPC-157 drugs?
No. Neither is authorized as a medicine, either in Europe or the United States. They are sold as research peptides.
What are their prices at MyPeptide?
KPV 10 mg costs €59.90 and BPC-157 10 mg costs €44.90. Delivery costs €10 and is free for orders over €160.
Do they have an analysis report?
Yes. KPV: Janoshik report #248290, 11.07 mg and 98.8% purity. BPC-157: report #248288, 12.91 mg and 99.9%.
Why is KPV in KLOW?
KLOW combines the GLOW mixture (GHK-Cu, BPC-157 and TB-500) and adds KPV, which is being studied for inflammation.
Sources: Brzoska et al., Endocr Rev 2008; Dalmasso et al., Gastroenterology 2008; Poolton et al., Acta Orthop Belg 2026; FDA, substances for compounding (April 2026); U.S. Department of Health, policy dated 30/10/2026; World Anti-Doping Agency, Prohibited List; Janoshik reports #248290 and #248288. MyPeptide products are intended exclusively for scientific laboratory research.
